June 2, 2025
- Hansoh Pharma grants Regeneron Pharmaceuticals an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, and Macau), to its investigational dual GLP-1/GIP receptor agonist.
- Hansoh Pharma receives an upfront payment of US$80 million and is eligible to receive development, regulatory, and sales milestone payments of up to US$1.93 billion, as well as double-digit royalties on potential future product sales.
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK),has granted Regeneron Phammaceuticals, Inc.(Regeneron, NASDAQ: REGN) an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong and Macau) to its
investigational dual GLP1/GIP receptor agonist HS-20094. HS-20094 has successfully completed multiple Phase II trials with positive efficacy and safety data and is currently being investigated in ongoing Phase III trial in China.
Under the agreement, Hansoh Pharma will receive an upfront payment of US$80 million and be eligible to receive up to US$1.93 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as double-digit royalties on potential future product sales.
The license agreement is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the US, and any necessary regulatory filings.
Eliza Sun, Executive Director of Board, Hansoh Pharma, said: “We are excited to enter this license agreement with Regeneron Pharmaceuticals, a company with a renowned leadership team and a well-established track record in pushing the boundaries of innovative drug development. We look forward to HS-20094 potentially reaching patients worldwide through this new partnership.”
About Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical company headquartered in China. The company is committed to addressing significant unmet medical needs in oncology, central nervous system (CNS) disorders, metabolic diseases, and autoimmune conditions. Hansoh Pharma has launched seven innovative compounds to date, building a diverse and growing commercial portfolio. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top three pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
For more information, please visit www.hspharm.com.
Statements
1. This announcement is intended for healthcare professionals only and not for advertising purposes.
2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.
3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.
4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
